Compare Sanofi SA (SNY) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Short Term Corporate Bond ETF — how do they compare? Sanofi SA trades at $40.16 (market cap $95.18B), while Vanguard Short Term Corporate Bond ETF trades at $77.28 (market cap $51.90B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 6.01% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| SNY | VCSH | |
|---|---|---|
Market Cap | $95.18B | $51.90B |
Volume | 2,995,646 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $52.34 | $80.20 |
52-Week Low | $39.51 | $77.03 |
Typical Hold Time | 94 Days | 52 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
VCSH trades at $77.285 with minimal daily movement (+0.02%). The technical outlook is bearish with moving averages signaling caution, though oscillators remain neutral. Recent news highlights VCSH's competitive 4.5% dividend yield and low 0.03% expense ratio, positioning it as a stable income alternative to CDs or stable value funds. The fund's short 2.7-year duration minimizes interest rate risk, but credit spreads remain tight, limiting near-term upside potential.
VCSH offers conservative investors higher yields than traditional safe-harbor investments with minimal volatility. The primary risk involves corporate credit exposure during economic downturns, while the main opportunity lies in its attractive risk-adjusted returns for short-term bond allocations. Current market sentiment is neutral with some institutional rotation observed in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
